Bioscience Firm Novonesis Raises Its 2026 Sales Growth Forecast

Novonesis grew sales 8% in the first half of 2026 and earned a profit margin of 37.7%. It now expects full-year sales growth of 7–8%, up from 5–7%. Management projects profit margins near the top of its 37–38% range. These results beat February forecasts, which had assumed currency drag after a weak end to 2025. (Source: Novonesis, Aug 19, 2026)